Skip to content

Effectiveness and Safety of Syzygium on Acne ( ESSA )

Effectiveness and Safety of Syzygium sp. Gel for Treatment of Acne: A Pilot Study

Status
Recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20180329008
Enrollment
30
Registered
2018-03-29
Start date
2018-04-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild to moderate acne Syzygium Effectiveness Safety Acne Herbal product

Interventions

Topical product (gel formulation) containing 2% of Syzygium extract,Topical product (gel formulation) containing 5% of Syzygium extract,Topical product containing gel base without Syzygium extract
2% Syzygium extract gel,5% Syzygium extract gel,Placebo gel

Sponsors

Medical Life Sciences Institute
Lead Sponsor
Institute of Dermatology
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 30 Years

Inclusion criteria

Inclusion criteria: Subjects with mild to moderate acne according to FDA's IGA guideline who approved by dermatologist

Exclusion criteria

Exclusion criteria: 1. Pregnant women (confirmed by test kids). 2. Nursing or breast feeding women. 3. Subjects with renal impairment or abnormal of liver enzyme. 4. Subject with other conditions such as wound, skin face abnormal, blood chemistry abnormal that would interfere with the assessments. 5. Subjects with history of allergy to Syzygium extract, sunscreen or other ingredients of experimental product. 6. Subjects with severe acne according to FDA’s IGA. 7. Subjects with acne requiring laser therapy. 8. Subjects with acne requiring isotretinoin or antibiotics such as doxycycline therapy 9. Subjects with acne requiring topical product within 3 months before starting date of study. 10. Subjects with other dermatological conditions such as eczema, seborrheic dermatitis requiring interfering treatment.

Design outcomes

Primary

MeasureTime frame
Any skin adverse events such as oedema, erythema, hot, scaling, dry skin, itching, pain, skin color At 30 minutes and week 2, 4, 6, 8, 10 , 12 after application the product Report or evaluation of clinical signs and symptoms by physicians and patients

Secondary

MeasureTime frame
Number of all types of acne, number of non-inflammatory or inflammatory acne, number of comำdone After application product for 2, 4, 6, 8, 10 , and 12 weeks Grading by Physician

Countries

Thailand

Contacts

Public ContactArchawin Rojanawiwat

Department of Medical Science

archawin191@yahoo.com0-2951-000-9

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026